Douwe Frank de Wit

Douwe Frank de Wit

Auto-generated profile, based on publicly available information

Douwe Frank de Wit

Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
DWDouwe F. de Wit
Douwe F. de Wit
NHNordin Hanssen
Nordin Hanssen
KWKoen Wortelboer
Koen Wortelboer
HHHilde Herrema
Hilde Herrema
ERElena Rampanelli
Elena Rampanelli
MNmax Nieuwdorp
max Nieuwdorp
Obesity has become a worldwide pandemic affecting more than 650 million people and is associated with a high burden of morbidity. Alongside traditional risk factors for obesity, the gut microbiome has been identified as a potential factor in weight regulation. Although rodent studies suggest a link between the gut microbiome and body weight, human evidence for causality remains scarce. In this Review, we postulate that existing evidence remains to establish a contribution of the gut microbiome to the development of obesity in humans but that modified probiotic strains and supraphysiological dosages of microbial metabolites may be beneficial in combatting obesity.

5 July 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
DWDouwe F. de Wit
Douwe F. de Wit
CSCoco M. Fuhri Snethlage
Coco M. Fuhri Snethlage
Elena RampanelliElena Rampanelli
Elena Rampanelli
KMKim Maasen
Kim Maasen
NWNoortje Walpot
Noortje Walpot
NHNordin Hanssen
Nordin Hanssen
Aims/hypothesis: The aim of this work was to investigate the association between macronutrient intakes and continuous glucose monitoring (CGM) metrics in individuals with type 1 diabetes. Methods: In 470 individuals with type 1 diabetes of the GUTDM1 cohort (65% female, median age 40 [IQR 28–53] years, median diabetes duration 15 [IQR 6–29] years), we used logistic regression to establish associations between macronutrient intakes and the CGM metrics time in range (TIR, time spent between 3.9–10.0 mmol/l blood glucose, optimally set at ≥70%) and time below range (TBR, <3.9 mmol/l blood glucose, optimally set at <4%). ORs were expressed per 1 SD intake of nutrient and were adjusted for other macronutrient intakes, age, sex, socioeconomic status, BMI, duration of type 1 diabetes, pump use, insulin dose and alcohol intake. Results: The median (IQR) TIR was 67 (51–80)% and TBR was 2 (1–4)%; the mean ± SD energy intake was 6879±2001 kJ, fat intake 75±31 g, carbohydrate intake 162±63 g, fibre intake 20±9 g and protein intake 70±24 g. A higher fibre intake and a lower carbohydrate intake were associated with higher odds of having a TIR≥70% (OR [95% CI] 1.64 [1.22, 2.24] and 0.67 [0.51, 0.87], respectively), whereas solely a higher carbohydrate intake was associated with TBR<4% (OR 1.34 [95% CI 1.02, 1.78]). Conclusions/interpretation: A higher fibre intake is independently associated with a higher TIR. A higher carbohydrate intake is associated with less time spent in hypoglycaemia, a lower TIR and a higher time above range. These findings warrant confirmatory (interventional) investigations and may impact current nutritional guidelines for type 1 diabetes. Graphical

14 July 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
DWDouwe Frank de Wit
Douwe Frank de Wit
CSCoco Marjolein Fuhri Snethlage
Coco Marjolein Fuhri Snethlage
RMRana Minab
Rana Minab
Elena RampanelliElena Rampanelli
Elena Rampanelli
PGPleun de Groen
Pleun de Groen
NHNordin Hanssen
Nordin Hanssen
Aims: As compared with C‐peptide, plasma proinsulin levels in individuals with long‐standing type 1 diabetes mellitus are relatively understudied, but may serve as a marker of stressed, yet alive β‐cells. Materials and Methods: We measured proinsulin and C‐peptide levels (detection limit <0.15 pmol/L and <0.05 nmol/L, respectively) in a cross‐sectional cohort of 482 individuals with type 1 diabetes mellitus and measured associations with diabetes duration, HLA haplotype and autoantibodies. Results: Proinsulin showed a biphasic decline with an initial decrease over 15 years followed by a stabilisation period, whereas C‐peptide showed a similar pattern but with an inflection point at ~8 years. Proinsulin and the proinsulin‐to‐C‐peptide ratio did not associate with variables associated with insulin resistance ( BMI , triglyceride levels, insulin/day/kg). Higher proinsulin‐ and C‐peptide levels correlated with higher levels of anti‐ GAD antibodies (Spearman ρ = 0.18 and 0.23 respectively, p < 0.05), but not with anti‐ IA2 . A high‐risk DR3 /3 HLA genotype associated with complete loss of C‐peptide ( OR 0.34, 95% CI 0.14–0.79) and proinsulin( OR 0.44, 95% CI 0.20–0.92). Conclusions/Interpretation: In type 1 diabetes mellitus, proinsulin levels remain detectable long after diagnosis, also in the absence of C‐peptide, implying the presence of stressed, yet alive β‐cells.

8 August 2026 in Diabetologia
Verified
Journal Article
Open access
PDF file
DWDouwe F. de Wit
Douwe F. de Wit
CSCoco M. Fuhri Snethlage
Coco M. Fuhri Snethlage
JLJohannes H. M. Levels
Johannes H. M. Levels
Elena RampanelliElena Rampanelli
Elena Rampanelli
AMAbraham S. Meijnikman
Abraham S. Meijnikman
NHNordin Hanssen
Nordin Hanssen
Aims/hypothesis: Although exocrine pancreatic insufficiency (EPI) is thought to be common in type 1 diabetes, little is known about the relationship of EPI with type 1 diabetes parameters or food intake and abdominal complaints. Characterising individuals with EPI could help prevent EPI-related complications such as malabsorption and osteoporosis. Methods: In a cross-sectional cohort of 443 individuals with type 1 diabetes (62% female, median age 42 years [IQR 29–54], mean BMI 25±4 kg/m 2 , median diabetes duration 16 years [IQR 6–29]), we associated faecal elastase (FE) levels, as a marker of EPI, with type 1 diabetes parameters and clinical features, using linear and Poisson regression models. Results: The mean FE level (±SD) was 349.5±146.8 µg/g faeces. A number of variables were independently associated with lower FE levels: older age (−10.97 µg/g faeces per 10 years; 95% CI −21.02, −0.92), longer diabetes duration (−13.09 µg/g per 10 years; 95% CI −23.54, −2.64), higher HbA 1c (−1.44 mmol/mol per 1 SD increase in FE levels, 95% CI −2.59, −0.30), male sex (−54.07 µg/g; 95% CI −81.41, −26.73) and smoking (−85.06 µg/g; 95% CI −128.52, −41.60). In a linear analysis, we found no evidence of associations between FE levels and markers of residual beta cell function, liver disease, macronutrient intakes or gastrointestinal complaints. Using a cut-off of 200 µg/g faeces, 76 individuals (17%) were found to have EPI, which was associated with a 4.31 mmol/mol (0.39%) higher HbA 1c (95% CI 1.35, 7.26), an 8% higher mean glucose (95% CI 2, 14), a 9% lower fibre intake (95% CI 1, 17) and an 8% lower energy intake (95% CI 1, 15). Conclusions/interpretation: The lack of evidence for associations with clinical parameters in this relatively healthy population of individuals with type 1 diabetes does not support the use of FE for routine screening for EPI. However, the high prevalence of low FE levels and their association with lower food intake and higher glucose levels justify a need for clinical awareness for EPI and its complications, especially in individuals with long diabetes duration.

12 March 2025 in Nederlands Tijdschrift voor Diabetologie
Verified
Journal Article
Open access
DWDouwe F. de Wit
Douwe F. de Wit
CSCoco M. Fuhri Snethlage
Coco M. Fuhri Snethlage
ERElena Rampanelli
Elena Rampanelli
KMKim Maasen
Kim Maasen
NWNoortje Walpot
Noortje Walpot
NHNordin Hanssen
Nordin Hanssen